At a glance
- Originator Bristol-Myers Squibb
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arterial thrombosis
Most Recent Events
- 21 Jul 1997 New profile
- 21 Jul 1997 Preclinical development for Arterial thrombosis in USA (Unknown route)